Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...
Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply ...
If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for Ypsomed Holding, this is the ...
Ypsomed Holding (SWX:YPSN) has recently announced a strategic partnership with Astria Therapeutics to develop an autoinjector for STAR-0215, underscoring its commitment to innovation and enhancing ...
The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...
Medical technology manufacturer plans to divest diabetes products business / Focus on injection systems © 2001-2024 Plasteurope.com | Imprint | Privacy | Cookie settings ...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Ypsomed Holding AG (VTX:YPSN) as an investment opportunity by estimating the company's future cash ...
Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy ...
0.13 = CHF87m ÷ (CHF1.2b - CHF513m) (Based on the trailing twelve months to September 2024). So, Ypsomed Holding has an ROCE of 13%. That's a pretty standard return and it's in line with the industry ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback